A: Obviously, many of our members who are on those medications and were successful with them were very, very disappointed
Regulatory Action State authorities have been directed to: Stop manufacturing and sales Investigate licensing approvals Submit compliance reports Biocon Leadership Transition and Strategic Shift Date: March 2728, 2026 Biocon announced the appointment of Shreehas Tambe as CEO and Managing Director, effective April 1, 2026
Gln deprivation increased only H3K9me3 (Supplementary Fig
Methods Eligibility criteria The PICOS strategy was defined as follows: P (participants) human subjects, I (interventions) oral LC treatment, C (comparisons) between supplementation and placebo, supplementation and control, or pre- and post- supplementation, O (outcomes) muscle variables, and S (study design) randomized controlled trials, non-randomized controlled trials, non-randomized non-controlled trials
Noteworthy, clinical efficacy was observed with both relapsed patients with ovarian and non-small cell lung cancers, and in the first-line treatment setting in non-small cell lung cancer patients (Sequist et al., 2009